Stonepine Capital Management LLC raised its holdings in Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) by 8.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 149,221 shares of the company’s stock after acquiring an additional 12,047 shares during the quarter. Stonepine Capital Management LLC’s holdings in Aprea Therapeutics were worth $491,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in APRE. LPL Financial LLC acquired a new position in Aprea Therapeutics in the fourth quarter valued at approximately $53,000. Landscape Capital Management L.L.C. acquired a new position in Aprea Therapeutics in the fourth quarter valued at approximately $116,000. Finally, BNP Paribas Financial Markets acquired a new position in Aprea Therapeutics in the fourth quarter valued at approximately $43,000. 34.19% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 25th.
Aprea Therapeutics Stock Up 3.3%
Shares of NASDAQ:APRE opened at $1.86 on Friday. Aprea Therapeutics, Inc. has a twelve month low of $1.41 and a twelve month high of $5.42. The stock’s 50 day moving average is $1.83 and its 200-day moving average is $2.83. The firm has a market capitalization of $10.28 million, a price-to-earnings ratio of -0.66 and a beta of 1.18.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.01). Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The company had revenue of $0.16 million for the quarter. Equities research analysts anticipate that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Further Reading
- Five stocks we like better than Aprea Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Savvy Investors Are Raising a Glass for Heineken Stock
- Canada Bond Market Holiday: How to Invest and Trade
- Top 4 ETFs for China Exposure After Tariff Relief
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Build a Complete Bond Portfolio With These 4 ETFs
Want to see what other hedge funds are holding APRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report).
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
